Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin
Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non Small Cell Lung Cancer (NSCLC)
Sponsor: Bristol-Myers Squibb
A PHASE3 clinical study on Lung Cancer - Non Small Cell Squamous, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 13 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jul 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Apr 2020 — Jul 2020 [monthly]
Completed PHASE3
-
Oct 2018 — Apr 2020 [monthly]
Completed PHASE3
-
Jun 2018 — Oct 2018 [monthly]
Completed PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE3
-
May 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jan 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
's-Hertogenbosch, Netherlands , Aalborg, Denmark , Aalst, Belgium , Akashi, Hyogo, Japan , Arequipa, Peru , Austin, United States , Bad Berka, Germany , Bangkok, Thailand , Barakaldo, Spain , Barretos, Brazil and 237 more locations